Gilead Sciences (GILD) — This has been a favorite biotech stock of mine since Nov. 19 near $37.50. On Aug. 29, at just over $60, I reiterated my positive opinion, citing an increase in earnings estimates by S&P and saying, “New hepatitis C drugs and stabilization in market share for their leading HIV drug are expected to enhance future earnings; thus GILD should be high on the list of biotech stocks in investors’ portfolios.”
On Nov. 20, Citigroup (C) reiterated its “buy” rating on GILD, increased its earnings estimate for fiscal 2014 by a nickel to $3.46, and upped its price target to $87 from $85.
Then, on Tuesday, S&P attributed the 3% dip in the stock to an unconfirmed Bloomberg report that Express Scripts (ESRX) raised concerns over the price of Gilead’s recently approved hepatitis C drug Sovaldi. S&P repeated its “strong buy” on the stock and target price of $94.
Technically GILD is still in a powerful bull channel with support at its 50-day moving average at $66 and a line connecting the highs of July and September and the low of November. MACD is slightly bearish. That and the rumors noted above could provide an opportunity to buy this top biotech at a lower price. My trading target is raised to $90 and my buy under price is $70.
P.S. – Traders looking to Serge Berger’s free Beat the Bell service every morning will be putting themselves in capable hands.
Serge has worked for InvestorPlace for years now, and has filled in for me on the rare occasion I take a few days off. Every time I return, I see plenty of reader compliments about Serge’s work.
Serge’s technique involves swing trades in stocks and ETFs that last anywhere from two days to four weeks. He is frequently successful in capturing high-probability trades that are set up at confluence zones of support/resistance using candlesticks as his charting method.
And Serge’s advice isn’t just one-time, one-way. Win or lose, he frequently revisits ideas after the fact to see what can be learned and what new trades can be made. More importantly, Serge connects with his readers, frequently answering questions and fielding some tough ones with aplomb.
I have no doubt that traders will be well-served by Beat the Bell and Serge’s daily flow of ideas.
– Sam Collins, InvestorPlace Chief Technical Analyst